NCT07486947
Unveiling Malnutrition and Metabolic Changes in Lung Cancer Patients: Setting the Basis for Precision Nutrition Models.
Recruiting · Not specified · Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares · registry updated 2026-03-23
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Malnutrition is a major cause of morbidity in a large portion of the population, particularly among people with specific medical conditions-such as lung cancer patients-and vulnerable population groups, such as pregnant women and the elderly. Lung cancer represents one of the most significant health problems in today's society, with an incidence of 1.8 million cases per year (13% of all cancer cases) and an estimated mortality of 1.6 million deaths annually, making it the leading cause of cancer-related death worldwide. The aim of this study is to collect data from different lung cancer patients in order to establish a precision nutrition recommendation model. The model will be capable of comprehensively characterizing the nutritional and metabolic status of individuals with nutritional impairment and, therefore, provide personalized dietary solutions based on the unique characteristics of each individual. To date, the number of personalized nutritional approaches to address malnutrition is relatively small; they have only been applied in very specific cases and generally have not addressed nutritional deficiencies as a whole but rather individual deficiencies....
Inclusion
- Study population cohort: Patients of both sexes Patients aged between 18 and 85 years Patients diagnosed with lung cancer (non-small cell and small cell) Patients treated with chemotherapy, immunotherapy, combinations of immunotherapy and biological therapy, patients receiving conservative therapy, without active treatment, or any other type of treatment, according to ESMO and NCCN guidelines for the management of metastatic lung cancer (small cell and non-small cell)
- Control population cohort: Volunteers of both sexes Volunteers aged between 18 and 85 years Volunteers free of oncological disease
Exclusion
- Study population cohort: Patients with uncontrolled chronic diseases Patients with acute gastrointestinal diseases
- Control population cohort: Volunteers with uncontrolled chronic diseases Volunteers with acute gastrointestinal diseases Volunteers who have had any type of oncological condition at any point in their lives Volunteers with diagnosed pulmonary pathology: chronic lung disease, asthma, pulmonary fibrosis, bronchiectasis, interstitial lung disease, recent pneumonia (3-6 months), moderate/severe sleep apnea, latent or previous tuberculosis with sequelae Volunteers with underlying autoimmune diseases: rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis Volunteers with active or chronic infections: HIV, hepatitis B or C, recurrent chronic infections, tuberculosis